- The national programme, to develop and progress start-up oncology projects, is being launched by Bruntwood SciTech at Alderley Park – the UK’s largest single site life science campus – with funding from Innovate UK and Cancer Research UK
- A unique collaboration of global pharmaceutical and healthcare companies, research institutions and public bodies will identify oncology innovations and leverage their combined insight and expertise to nutri-los em start-ups prontos para investimento
- seu objetivo é apresentar projetos viáveis de oncologia muito mais rapidamente, a fim de aumentar significativamente sua probabilidade de sucesso comercial
- O programa de desenvolvimento de oncologia visa encontrar e desenvolver inovações que melhorem o diagnóstico e o tratamento do câncer || Forças para ajudar a acelerar a tradução da pesquisa emergente de câncer no Reino Unido para os benefícios dos pacientes. Reino Unido. Essa abordagem ajudará as inovações bem-sucedidas a progredir rapidamente em proposições investigáveis e desinvestíveis, prontas para atender às necessidades dos pacientes. Como parceiro de entrega do programa, a Catapult, um centro nacional de pesquisa e desenvolvimento na descoberta de medicamentos, trabalhará em estreita colaboração com os pesquisadores e start-ups participantes selecionados, para ajudá-los a desenvolver o programa de entrega totalmente validado, cronometrado, custado, com os parceiros de entrega, a mais de uma espécie de foco em que se concentra em um investimento contínuo e mais amplo de um investimento futuro. O modelo que normalmente abrange várias áreas terapêuticas e é suportado por um ou dois especialistas em um campo específico. O Programa de Desenvolvimento de Oncologia de nove meses, em última análise, fornecerá aos investidores em potencial planos detalhados sobre como cada empresa fornecerá dados importantes e marcos de valor durante os dois a três anos seguintes.
Some of the biggest names in UK cancer research and clinical excellence and four major global pharmaceutical and healthcare companies are combining forces to help accelerate the translation of emerging cancer research in the UK into patient benefits.
The Oncology Development Programme at Alderley Park is being led by Bruntwood SciTech, a partnership between Bruntwood and Legal & General, and funded by Innovate UK and Cancer Research UK, as part of Cancer Research UK’s Entrepreneurial Programmes Initiative aimed to develop and nurture an entrepreneurial culture amongst cancer researchers in the UK.
Its goal is to bring forward commercially viable ideas much more quickly, ready to take on new funding or collaborators in order to significantly increase their likelihood of commercial success. This approach will help successful innovations progress quickly into de-risked, investable propositions ready to meet patients’ needs.
A collaboration of AstraZeneca, Johnson & Johnson Innovation, GlaxoSmithKline, Roche, The Christie NHS Foundation Trust, Medicines Discovery Catapult and the Manchester Cancer Research Centre will support researchers and start-ups aiming to develop their early-stage innovations. As delivery partner for the programme, Medicines Discovery Catapult, a national hub for research and development in drug discovery, will work closely with the selected participating researchers and start-ups, to help them develop fully validated, timed, costed, project plans with delivery partners in place, vastly improving their likelihood of attracting future investment.
The creation of such a broad collaboration focused solely in oncology is different from the traditional accelerator programme model which typically covers multiple therapeutic areas and is supported by one or two specialists from within a particular field. The nine-month Oncology Development Programme will ultimately provide potential investors with detailed plans on how each company will deliver key data and value milestones during the following two to three years.
Dr. Kath Mackay, diretor administrativo da Bruntwood Scitech - Alderley Park, disse: “Este é um projeto realmente emocionante e exclusivo que ajudará a transformar algumas das idéias mais promissoras em pesquisas de câncer hoje em projetos investíveis que melhorarão a maneira como os pacientes com câncer não são diagnosticados e tratados durante o curso de sua vida. Pandemia, financiamento e pesquisa sobre o espancamento do câncer sofreu. Nosso novo programa não poderia ser lançado em um momento mais crítico e, como na corrida para encontrar uma vacina covid-19, sinaliza um grande esforço colaborativo envolvendo líderes globais. Negócios. Os participantes do Programa de Desenvolvimento de Oncologia terão a oportunidade de acessar o conjunto profundo de talentos e conhecimentos de todo o Reino Unido. ”
“It’s no secret that while the life sciences sector and indeed the wider world has understandably been focused on the pandemic, funding and research into beating cancer has suffered. Our new programme couldn’t be launching at a more critical time and, as with the race to find a Covid-19 vaccine, it signals a major collaborative effort involving global leaders.
“By leveraging the best-in-class infrastructure and expertise at Alderley Park and the wider Bruntwood SciTech network, we can help the participants stay hands-on, doing what they do best, rather than having to down tools and focus on running a business.
“Bruntwood SciTech’s national network of innovation districts includes the leading precision medicine and health innovation campus Citylabs located at Manchester University NHS Foundation Trust’s Oxford Road hub and the newly announced Birmingham Health Innovation Campus. The Oncology Development Programme’s participants will have the opportunity to access the deep pool of talent and expertise from right across the UK.”
Tony Hickson, diretor de negócios do Cancer Research UK, disse:“ Estamos encantados em ver esse programa chegar a fruição como parte de nossa iniciativa de programas empreendedores. No final do dia, queremos trazer novos tratamentos potencialmente que salvam vidas para os pacientes. Nossa iniciativa visa impulsionar o empreendedorismo entre os pesquisadores de câncer e incentivar a inovação na interface da academia e da indústria que pode ajudar a trazer idéias do banco ao lado da cama. Os candidatos. ” Especialistas científicos e de negócios do Manchester Cancer Knowledge Quarter, Medicines Discovery Catapult, principais investidores e a indústria farmacêutica. Isso permitirá que as start-ups acelerem suas tecnologias emergentes para a comercialização, oferecendo benefícios significativos à saúde para pacientes com câncer. ” Laboratório. Downtown in Business
“The infrastructure and expertise that Alderley Park and the pharma collaborators bring would put any researchers that go through the programme in a fantastic position to translate their research. I look forward to following the progress of the successful applicants.”
Richard Hebdon, Head of Health & Medicine, Innovate UK added: “Now more than ever, the UK has to focus on cancer research and innovation. Understandable attention has been on Covid-19, yet we must unleash our capacity for innovation in oncology. This unique and exciting collaboration with Cancer Research UK and Alderley Park will boost the commercialisation potential of UK oncology start-ups. The programme will receive great support from scientific and business experts from the Manchester Cancer Knowledge Quarter, Medicines Discovery Catapult, key investors and the pharma industry. This will allow start-ups to accelerate their emerging technologies towards commercialisation whilst delivering significant health benefits for cancer patients.”
Participants that progress through the programme will receive up to £60,000 of grant funding to support the development of their business plans, including provision for salary replacement. They will also receive support to develop an optional ‘virtual R&D’ business model, provided by the Medicines Discovery Catapult, without the need to establish a research laboratory.
A series of virtual workshops and Q&A sessions to support applications to the Oncology Development Programme will be held throughout November and December.
For more information on applying for the programme, visit: www.alderleypark.co.uk/oncologyprogramme.
